Stage III and IV breast cancer patients have been treated with tyrosine kinase inhibitors (TKIs), including some that inhibit DDR2 (e.g. dasatinib and imatinib), alone and in combination with other therapies (Day et al., 2008; Bai et al., 2014). The gene discussed is DDR2; the disease is breast cancer.